The drug, Kevzara, was FDA-approved in 2017 to treat rheumatoid arthritis, but the drugmakers said it could also help minimize damage to the lungs and respiratory system caused by the immune system’s response to the new coronavirus. The drug wouldn’t, however, treat the underlying virus.
The drugmakers think Kevzara could be effective against COVID-19, the disease caused by the coronavirus, because of a report from Chinese researchers that a similar drug from Roche, called Actemra, helped a small group of COVID-19 patients recover, according to the Journal.
Both drugs block proteins called interleukin-6, or IL-6, which trigger the body’s immune and inflammatory response. Blocking the proteins could stop the body from attacking itself, the Journal reported.
Regeneron’s chief scientific officer, George Yancopoulos, told the Journal that it is hoping to start the trial in the next couple of weeks. The drugmaker reportedly is holding talks with the FDA, New York’s health commissioner and hospitals to set up the trial.
The trial would only study the drug’s response in patients with severe to critical COVID-19 cases.
Sanofi, based in Paris, also hopes to begin a clinical trial overseas as soon as possible, the Journal reported.
Read the full article here.
More articles on pharmacy:
CMS launches Part D plan to lower insulin costs
15 largest pharmacies in the US
Trump sends list of drug-pricing policy proposals to Capitol Hill
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
